ATOS — Atossa Therapeutics Share News
0.000.00%
Last trade - 00:00Atossa Therapeutics rises as Canada permits phase 2 of cancer drug trial
Brief: Atossa Therapeutics Provides Enrollment Update For Ongoing Phase 2 Karisma-Endoxifen Clinical Trial
Brief: Atossa Therapeutics, Quantum Leap Healthcare Provides Enrollment Update
Brief: Atossa Therapeutics Announces $10M Stock Repurchase Program
Brief: Atossa Therapeutics Says On June 21, Co Received Formal Non-Compliance Notice From Listing Qualifications Staff Of Nasdaq
Brief: Atossa Completes Enrollment Of Pharmacokinetic Run-In Cohort In Phase 2 Evangeline Clinical Trial Evaluating (Z)-Endoxifen As
Brief: Atossa Appoints Life Sciences Financial And Operations Industry Veteran Greg Weaver As Chief Financial Officer
Brief: Atossa Appoints Life Sciences Financial And Operations Industry Veteran Greg Weaver As Chief Financial Officer
U.S. RESEARCH ROUNDUP-Empire State, Integra Lifesciences, Lowe's Companies
Brief: Societal Cdmo Enters Agreement With Atossa Therapeutics To Provide Clinical Trial Services (CTS)
Atossa Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Atossa Therapeutics Announces First Quarter 2023 Financial Results And Provides Corporate Update
Atossa Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Atossa Therapeutics Says Had Until April 3 To Regain Nasdaq Compliance
U.S. RESEARCH ROUNDUP- Marathon Petroleum, Nvidia, Repligen
Atossa Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Atossa Therapeutics Announces Year-End 2022 Financial Results
Brief: Atossa Therapeutics And Quantum Leap Healthcare Announce New Study Arm To Evaluate (Z)-Endoxifen In The Ongoing I-Spy 2 Clinical Trial
Brief: Atossa Therapeutics Says Does Not Hold Cash Deposits Or Securities At Silicon Valley Bank